Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestogen (synthetic progestin) presented as a 52 mg intrauterine system for intrauterine use. It provides long‑acting reversible contraception and is also indicated for the management of heavy menstrual bleeding and endometriosis‑associated pain in women of reproductive age and is approved for use in the European Union.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics.

Mirena, a levonorgestrel-releasing intrauterine system, is used in several gynecologic conditions.

Contraception (up to 5 years): provides highly effective, reversible birth control for women seeking long‑acting contraception. Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with excessive bleeding. Endometriosis‑associated pain: alleviates chronic pelvic pain related to endometriosis.

Levonorgestrel IUS may be associated with a range of adverse events, which are categorized by frequency and severity.

Common Side Effects: - Irregular bleeding or spotting - Amenorrhea (absence of periods) - Headache - Breast tenderness - Acne or oily skin - Mood changes

Serious or Rare Side Effects: - Pelvic inflammatory disease - Uterine perforation during insertion - Expulsion of the device - Ectopic pregnancy if contraception fails - Ovarian cyst formation - Severe allergic reaction (anaphylaxis)

Before insertion and during use, several precautions should be observed to ensure safety and effectiveness. - Pregnancy testing: confirm non‑pregnant status prior to insertion. - Regular follow‑up: schedule post‑insertion visits to verify correct device position. - Contraindications: avoid in women with active pelvic infection, known uterine anomalies, or unexplained vaginal bleeding. - Medication interactions: consider reduced efficacy when used with enzyme‑inducing drugs such as certain anticonvulsants. - Smoking: advise cessation in women over 35 who smoke, due to increased cardiovascular risk. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Mirena can interact with other medicines, affecting its contraceptive reliability.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may lower levonorgestrel effectiveness. - Rifampin and other strong enzyme‑inducing antibiotics: may reduce contraceptive reliability.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): possible modest reduction in hormone activity. - Protease inhibitor antiretrovirals: may alter levonorgestrel levels. - St. John’s wort (hypericum perforatum): may decrease contraceptive efficacy.